The new space has capacity for more than 100 employees and is expected to reinforce Cyient’s position in the Australian market.
This marks the Sydney-based IT managed solutions provider’s fourth acquisition of 2024.
Cambium Bio is a regenerative medicine company with a dry eye disease treatment in the works.
The addition of The APP Group’s services allows Bureau Veritas to diversify its portfolio and grow within the Australian market.
Yoshikazu Oishi will be the regional leader for the connectivity tech company’s Japanese operations.
AI is a top priority in Australia, and these Sydney companies are leading the way with their platforms.
The acquisition aims to improve existing services and help the company expand into new markets across the continent.
These Sydney healthtech companies are developing novel medical treatments and health platforms for patients.
The funding award comes from a government program focused on academic and industry partnerships to bolster defense tech.
The data centers in Melbourne and Sydney will extend Consilio’s litigation and investigation services on the continent.
We're always looking for news.
